Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Increased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,420,949 shares of the medical research company's stock after buying an additional 257,462 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.63% of Thermo Fisher Scientific worth $1,259,450,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Cypress Advisory Group LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $253,000. Intact Investment Management Inc. increased its position in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after acquiring an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $1,121,000. Clear Harbor Asset Management LLC boosted its stake in Thermo Fisher Scientific by 10.4% in the 4th quarter. Clear Harbor Asset Management LLC now owns 13,418 shares of the medical research company's stock worth $6,981,000 after purchasing an additional 1,269 shares during the period. Finally, Fifth Third Bancorp raised its stake in Thermo Fisher Scientific by 11.6% during the 4th quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock valued at $174,305,000 after purchasing an additional 34,917 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.4%

Shares of TMO opened at $413.75 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The firm has a market capitalization of $156.19 billion, a P/E ratio of 25.03, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a 50-day simple moving average of $451.89 and a 200-day simple moving average of $508.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business posted $5.11 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Analysts Set New Price Targets

Several brokerages have recently commented on TMO. Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Citigroup dropped their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. UBS Group decreased their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $607.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.